The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A three-dimensional human neural cell culture model of Alzheimer’s disease
Open accessAbstract
Alzheimer's disease is the most common form of dementia, characterized by two pathological hallmarks: amyloid-β plaques and neurofibrillary tangles. The amyloid hypothesis of Alzheimer's disease posits that the excessive accumulation of amyloid-β peptide leads to neurofibrillary tangles composed of aggregated hyperphosphorylated tau. However, to date, no single disease model has serially linked these two pathological events using human neuronal cells. Mouse models with familial Alzheimer's disease (FAD) mutations exhibit amyloid-β-induced synaptic and memory deficits but they do not fully recapitulate other key pathological events of Alzheimer's disease, including distinct neurofibrillary tangle pathology. Human neurons derived from Alzheimer's disease patients have shown elevated levels of toxic amyloid-β species and phosphorylated tau but did not demonstrate amyloid-β plaques or neurofibrillary tangles. Here we report that FAD mutations in β-amyloid precursor protein and presenilin 1 are able to induce robust extracellular deposition of amyloid-β, including amyloid-β plaques, in a human neural stem-cell-derived three-dimensional (3D) culture system. More importantly, the 3D-differentiated neuronal cells expressing FAD mutations exhibited high levels of detergent-resistant, silver-positive aggregates of phosphorylated tau in the soma and neurites, as well as filamentous tau, as detected by immunoelectron microscopy. Inhibition of amyloid-β generation with β- or γ-secretase inhibitors not only decreased amyloid-β pathology, but also attenuated tauopathy. We also found that glycogen synthase kinase 3 (GSK3) regulated amyloid-β-mediated tau phosphorylation. We have successfully recapitulated amyloid-β and tau pathology in a single 3D human neural cell culture system. Our unique strategy for recapitulating Alzheimer's disease pathology in a 3D neural cell culture model should also serve to facilitate the development of more precise human neural cell models of other neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Beading or blebbing in neurites is a marker of dystrophic neurites in the AD brain (3, 42, 43).”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In AD, tau protein becomes hyperphosphorylated, resulting in tau dissociating from microtubules and forming insoluble tau aggregates in the neurites and cell bodies (3, 37).”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In iPSC-derived neurons from both FAD- and SAD-patients, pTau aberrantly accumulates at early time points (Choi et al., 2014, Israel et al., 2012, Moore et al., 2015, Muratore et al., 2014, Ochalek et al., 2017, Shi et al., 2012).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Choi et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Modeling these pathological hallmarks has largely relied on transgenic cellular and animal models harboring genetic mutations linked to ADAD (3–5).”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“As for human neurons, previous studies focused on overexpressing mutant APP and Presenilin in REN stem cells grown in a 3D culture (3), which differs from patient-specific LOAD model that relies on the endogenous recapitulation of AD-associated phenotypes as provided in this study.”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [3]
In the citing paper
“one study revealed that familial AD (FAD) mutations in β-amyloid precursor protein and presenilin 1 induced robust extracellular deposition of amyloid-β in a human neural stem-cell-derived 3D culture system85.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [85]
In the citing paper
“the 3D-differentiated neuronal cells expressing FAD mutations exhibited aggregates of phosphorylated tau as well as filamentous tau.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [85]
In the citing paper
“A 3D in vitro culture system consisting of human neurons differentiated from induced pluripotent stem cells overexpressing human APP containing FAD mutations generates robust Aβ42 production and amyloid deposition. Importantly, this model also develops elevated phospho-tau levels and fibrillary tau aggregates, suggesting that elevated Aβ levels alone are sufficient to drive tau pathology in human”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Choi et al., 2014
In the citing paper
“It was recently shown that development of a 3D culture of human neural stem cells transfected with APPK670N/M671L/V717I and PS1ΔE9 in Matrigel scaffolding resulted in the extracellular aggregation of Aβ into plaques and the intracellular aggregation of tau in dystrophic neurites and the cell soma [23, 77].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Cerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Self-citationProbing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C., Lee, V. M. ‐., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,211
Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.009 · Cited by 741
Modeling familial Alzheimer's disease with induced pluripotent stem cells
Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H., & Suzuki, N. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr394 · Cited by 599
Cohen, R. M., Rezai-Zadeh, K. P., Weitz, T. M., Rentsendorj, A., Gate, D., Spivak, I. E., Bholat, Y., Vasilevko, V., Glabe, C. G., Breunig, J. J., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3672-12.2013 · Cited by 555
Muratore, C. R., Rice, H. C., Srikanth, P., Callahan, D. G., Shin, T., Benjamin, L. N. P., Walsh, D. M., Selkoe, D. J., & Young-Pearse, T. L. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu064 · Cited by 379
Donato, R., Miljan, E., Hines, S. J., Aouabdi, S., Pollock, K., Patel, S., Edwards, F. A., & Sinden, J. D. (2007) · BMC Neuroscience · doi:10.1186/1471-2202-8-36 · Cited by 312
Bioengineered functional brain-like cortical tissue
Tang‐Schomer, M. D., White, J. D., Tien, L. W., Schmitt, L. I., Valentin, T. M., Graziano, D. J., Hopkins, A. M., Omenetto, F. G., Haydon, P. G., & Kaplan, D. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324214111 · Cited by 305
1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3β
Kunick, C., Lauenroth, K., Leost, M., Meijer, L., & Lemcke, T. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.10.062 · Cited by 180
Neuronal and microglial involvement in beta-amyloid protein deposition in Alzheimer's disease.
Cras, P. P., Kawai, M., Siedlak, S. L., Mulvihill, P., Gambetti, P. L., Lowery, D. E., Gonzalez‐DeWhitt, P. A., Greenberg, B., & Perry, G. L. (1990) · Europe PMC (PubMed Central) · Cited by 174
Sproul, A. A., Jacob, S., Pre, D., Kim, S. H., Nestor, M. W., Navarro-Sobrino, M., Santa-Maria, I., Zimmer, M., Aubry, S., Steele, J. W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084547 · Cited by 162
[25] Use of excitatory amino acids to make axon-sparing lesions of hypothalamus
Nadler, J. V., & Evenson, D. A. (1983) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(83)03027-x · Cited by 149
Planel, E., Bretteville, A., Liu, L., Virág, L., Du, A. L., Yu, W. H., Dickson, D. W., Whittington, R. A., & Duff, K. (2009) · The FASEB Journal · doi:10.1096/fj.08-122424 · Cited by 138
3D Differentiation of Neural Stem Cells in Macroporous Photopolymerizable Hydrogel Scaffolds
Li, H., Wijekoon, A., & Leipzig, N. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048824 · Cited by 108
Selecting a Mouse Model of Alzheimer’s Disease
Chin, J. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-744-0_13 · Cited by 98
The role of tau in Alzheimer's disease
Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00002-0 · Cited by 85
GSK-3α/β kinases and amyloid production in vivo
Jaworski, T., Dewachter, I., Lechat, B., Gees, M., Kremer, A., Demedts, D., Borghgraef, P., Devijver, H., Kügler, S., Patel, S., et al. (2011) · Nature · doi:10.1038/nature10615 · Cited by 69
Wagner, S. L., Zhang, C. M., Cheng, S., Nguyen, P. A. H., Zhang, X., Rynearson, K. D., Wang, R., Li, Y., Sisodia, S. S., Mobley, W. C., et al. (2014) · Biochemistry · doi:10.1021/bi401537v · Cited by 50
Self-citationKirby, L. A., Schott, J. T., Noble, B. L., Mendez, D. C., Caseley, P. S., Peterson, S. C., Routledge, T. J., & Patel, N. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039329 · Cited by 49
Human stem cell-derived neurons: a system to study human tau function and dysfunction
Iovino, M., Patani, R., Watts, C., Chandran, S., & Spillantini, M. G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013947 · Cited by 40
Mazemondet, O., Hübner, R., Frahm, J., Koczan, D., Bader, B., Weiss, D. G., Uhrmacher, A. M., Frech, M. J., Rolfs, A., & Luo, J. (2011) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-011-0021-0 · Cited by 39
Biochemical Isolation of Insoluble Tau in Transgenic Mouse Models of Tauopathies
Julien, C., Bretteville, A., & Planel, E. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-551-0_32 · Cited by 37
Transgenic mouse models of Alzheimer's disease: phenotype and mechanisms of pathogenesis
Duff, K. (2001) · Biochemical Society Symposia · doi:10.1042/bss0670195 · Cited by 27
Use of Excitatory Amino Acids to Make Axon-Sparing Lesions of Hypothalamus
Nadler, J. V., & Evenson, D. A. (1989) · Elsevier eBooks · doi:10.1016/b978-0-12-185150-7.50060-9 · Cited by 25
iPSCs to the Rescue in Alzheimer's Research
Choi, S. H., & Tanzi, R. E. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.02.011 · Cited by 23
Self-citationProtection of neurons derived from human neural progenitor cells by veratridine
Morgan, P. J., Ortinau, S., Frahm, J., Krüger, N., Rolfs, A., & Frech, M. J. (2009) · Neuroreport · doi:10.1097/wnr.0b013e32832fbf49 · Cited by 20
Flagged first, then by citations
Research works printed but not linked: 1
- Higuchi, M., Trojanowski, J. Q. & Lee, V. M.-Y. Tau protein and tauopathy. Neuropsychopharmacology: The Fifth Generation of Progress (eds Davis, K. L., Charney, D., Coyle, J. T. & Nemeroff, C. ) 1339–1354 (Lippincott, Williams & Wilkins, 2002)
Cited by
Sorted by citations
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Microglia emerge as central players in brain disease
Salter, M. W., & Stevens, B. (2017) · Nature Medicine · doi:10.1038/nm.4397 · Cited by 1,767
Metadata
- Authors
- Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., Klee, J. B., Zhang, C., Wainger, B. J., Peitz, M., Kovacs, D. M., Woolf, C. J., Wagner, S. L., Tanzi, R. E., & Kim, D. Y.
- Affiliations
- Harvard University (US)
- University of Bonn (DE)
- Boston Children's Hospital (US)
- Whitehead Institute for Biomedical Research (US)
- University of California San Diego (US)
- Corresponding author
- Tanzi, Rudolph E.
- Kim, Doo Yeon
- ORCID
- Venue
- Nature
- Published
- 2014-10-12
- Volume
- 515
- Issue
- 7526
- Pages
- 274-278
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4366007
- OpenAlex
- W2126231259
- Cited by
- 1,195
- References
- 30
- Citations by year
- 2026: 67 · 2025: 75 · 2024: 95 · 2023: 88 · 2022: 112 · 2021: 111 · 2020: 141 · 2019: 109 · 2018: 109 · 2017: 87 · 2016: 97 · 2015: 87 · 2014: 14
- FWCI
- 63.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Massachusetts General Hospital
- Cure Alzheimer's Fund
- University of Edinburgh
- National Institute on Aging (5P01 AG15379, P01AG015379, R21AG031483, RF1AG048080, P50AG005134, R01AG014713, P01AG004953, P30AG062421)
- National Institute of Mental Health (R37MH060009)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK057521, P30DK043351)
- National Institute of Neurological Disorders and Stroke (P30NS045776, R01NS045860)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30HD018655)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, familial Alzheimer's disease, amyloid plaques, tauopathy, neurofibrillary tangles, amyloid hypothesis, presenilin 1 mutations, human neural stem cells, 3D cell culture, human neurons, beta-secretase inhibition, gamma-secretase inhibition, tau phosphorylation, drug screening model
- MeSH terms
- Alzheimer Disease, Cell Differentiation, Drug Evaluation, Preclinical, Extracellular Space, Humans, Microtubule-Associated Proteins, Models, Biological, Phosphorylation, Reproducibility of Results, Amyloid beta-Peptides, Neurites, tau Proteins, Cell Culture Techniques, Glycogen Synthase Kinase 3, Presenilin-1, Neural Stem Cells, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
